Stay updated with breaking news from Simple Western. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Impurities in protein products can be dangerous and impact efficacy. For example, protein impurities in final drug products could lead to undesirable...
Operator Good morning, and welcome to the Bio-Techne Earnings Conference Call for the Third Quarter of Fiscal Year 2021. At this time, all participants have been placed in listen-only mode and the call will be open for questions following management's prepared remarks. During our Q&A session, please limit yourself to one question and a follow-up. I would now like to turn the call over to David Clair, Bio-Techne's Senior Director, Investor Relations and Corporate Development. David Clair -- Senior Director-Investor Relations and Corporate Development Good morning, and thank you for joining us...
MINNEAPOLIS, April 8, 2021 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ:TECH) today announced that ProteinSimple, a Bio-Techne brand, released Abby, its next generation chemiluminescence system that automates traditional Western blotting. This latest addition to the Simple Western product family offers picogram-level sensitivity through chemiluminescence detection along with the ability to perform sequential immunoassays using RePlexâ¢. Abby is accompanied by the latest version of Compass software for Simple Western that adds to its publication-ready data analysis tools exten...
Operator Good morning, and welcome to the Bio-Techne earnings conference call for the Second Quarter of Fiscal Year 2021. [Operator Instructions] I would now like to turn the call over to David Clair, Bio-Techne's Senior Director, Investor Relations and Corporate Development. David Clair -- Senior Director, Investor Relations & Corporate Development Good morning, and thank you for joining us. On the call with me this morning are Chuck Kummeth, Chief Executive Officer; and Jim Hippel, Chief Financial Officer of Bio-Techne. Before we begin, let me briefly cover our safe harbor statement. Some ...